Back to search

National and Kapodistrian University of Athens

Cardiovascular risk evaluation and attainment of therapeutic targets in antiphospholipid syndrome

Abstract

dc:description

Topic-Aim: The investigational aims underlying the work detailed in this doctoral dissertation include the evaluation of cardiovascular risk, prevalence and target attainment of traditional cardiovascular risk factors (CVRFs) in patients with antiphospholipid syndrome (APS). We also aimed to assess these outcomes in patients with systemic lupus erythematosus (SLE) with or without coexistent APS, in the context of a multicentre, multi-ethnic SUrvey of cardiovascular Risk Factors in patients with SLE and APS (SURF-SLE and APS), presented within this dissertation. Methods-Procedures: Adult patients with APS followed in the outpatient Rheumatology clinic of the First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens Medical School (Laikon General Hospital) were assessed for eligibility. APS patients aged ≥ 70 years, with symptomatic or clinically evident atherosclerotic cardiovascular disease (CVD), active malignancy, pregnancy, acute illness or diabetes mellitus (DM) were excluded. Participants were matched in a 1:1 ratio for age and sex with eligible patients with rheumatoid arthritis (RA) and DM followed in the corresponding outpatient Units of the same Department. For the SURF-SLE and APS project, adult SLE patients with or without concomitant APS followed between 2015 and 2020 (extended to 2022 for the centres not able to complete the survey by the end of 2020 due to the COVID-19 pandemic) were eligible and were recruited from the Rheumatology Unit of our Department and 26 other research centers with experience in SLE and/or APS, spanning 24 countries across five continents. Patient characteristics, along with various disease-related and CVRF parameters were retrieved from medical records at the time of the patients’ visit at the department. Patients with APS were categorised based on their initial visit into two subgroups (2011–2015 and 2016–2020 APS subgroups) and were compared with age- and sex-matched RA and DM patients. In the SURF-SLE and APS study, the outcomes were assessed in the entire SLE cohort and potential differences were examined according to participating country income level and APS coexistence. The Systematic Coronary Risk Evaluation (SCORE) tool, endorsed by the European Society of Cardiology (ESC), was employed for individual CVD risk stratification. CVRF therapeutic targets were defined according to the ESC guidelines, corresponding to the time periods assessed in this dissertation. Individual and composite CVRF control was compared between APS subgroups, and in APS versus RA and DM. The presence of metabolic syndrome (MetS) was evaluated based on three different sets of diagnostic criteria: Joint Interim Statement (JIS), International Diabetes Federation (IDF) and modified National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII). Multivariate logistic regression models were applied to assess potential associations of MetS with different patient groups, as well as various clinical, laboratory and subclinical atherosclerosis parameters (presence of carotid and femoral atherosclerotic plaques detected via vascular ultrasound at the time of patients’ visit) specifically in APS patients. Results-Conclusions: We identified a comparable or higher prevalence of CVRFs in patients with APS compared to age-/sex-matched patients with RA and DM but low CVRF target attainment in APS according to the ESC guidelines, ranging between 31% and 86% for the targets of exercise, body mass index (BMI), lipids (low-density lipoprotein [LDL], high-density lipoprotein [HDL], triglycerides), smoking and blood pressure (BP). Despite improvements between 2011–2015 and 2016–2020, CVRF control in high/very high-risk patients with APS remained suboptimal at 12%, 18%, 24% and 35% for LDL, waist circumference, exercise and BMI, respectively, and 59%–65% for triglycerides, HDL and BP, in the 2016–2020 subgroup. CVRF control was worse in APS compared to RA for smoking (p=0.014), HDL (p<0.001), waist circumference (p=0.042) and five CVRFs (p=0.030), and compared to DM for exercise (p=0.077). Similar results were found in the sensitivity analysis. The prevalence of MetS was 23.9%, 23.2%, 20.3% (according to JIS, IDF, modified NCEP-ATPIII criteria, respectively) in APS versus 17.4%, 17.4%, 13% in RA (p=0.181, p=0.231, p=0.106, respectively), and 44.2%, 44.2%, 40.6% in DM patients. Multivariate analysis showed that patients with SLE/APS had approximately a 2.5-fold higher risk of MetS compared to RA patients. MetS in APS was independently associated with arterial thrombosis (odds ratio 3.5, p=0.030). The odds ratio for MetS was 1.16 for each unit increase in C-reactive protein levels based on JIS and IDF criteria, and 1.49 and 1.47 for each unit increase in uric acid levels using the IDF and modified NCEP-ATPIII models, respectively. APS patients with atherosclerotic carotid plaques had 4 to 6.5-fold higher risk of MetS. The odds of MetS decreased by 26% with an increase in physical activity by one hour per week.In the SURF-SLE and APS study, a high prevalence of CVRFs (hypertension in 35.6% [1210 of 3398], obesity in 23.7% [751 of 3169], and hyperlipidaemia in 19.8% [650 of 3279]) and suboptimal control of modifiable CVRFs (BP <130/80 mm Hg, BMI, and lipids) were observed in the entire SLE group. Higher prevalence of CVRFs but better BP (target of < 130/80 mm Hg) (54.9% [1170 of 2132 patients] vs 46.8% [519 of 1109 patients], p<0.001) , and lipid control (75.0% [895 of 1194 patients] vs 51.4% [386 of 751 patients], p<0.001 for HDL; 66.4% [769 of 1158 patients] vs 60.8% [453 of 745 patients], p=0.013 for non-HDL; 80.9% [1017 of 1257 patients] vs 61.4% [486 of 792 patients], p<0.001 for triglycerides) were noted in patients from high-income versus middle-income countries. Patients with SLE/APS had a higher prevalence of hypertension (47.1% [262 of 556 patients] vs 34.6% [736 of 2125 patients], p<0.001), hyperlipidaemia (34.6% [189 of 547 patients] vs 21.2% [447 of 2105 patients], p<0.001), obesity (29.0% [150 of 518 patients] vs 24.0% [471 of 1960 patients], p=0.021), and type II DM (7.9% [43 of 547 patients] vs 5.1% [107 of 2084 patients], p=0.014), and significantly lower attainment for BMI (37.1% [192 of 518 patients] vs 50.5% [989 of 1960 patients], p<0.001) , LDL (48.3% [156 of 323 patients] vs 61.7% [771 of 1249 patients]; p<0.001), and non-HDL (55.7% [175 of 314 patients] vs 65.9% [807 of 1224 patients], p=0.001) targets compared to SLE/non-APS patients. In conclusion, traditional CVRFs are prevalent in patients with APS at comparable or higher rates than in patients with RA and DM. Arterial thrombosis, CVD risk biomarkers, physical activity, and subclinical atherosclerosis in APS are strongly associated with the presence of MetS, which is diagnosed in one-fourth of these patients. Despite noted improvements in CVRF control, target attainment in APS remains inadequate, particularly in patients classified as high and very high CVD risk. Similarly with APS, patients with SLE are also characterised by a high prevalence yet inadequate control of traditional CVRFs, especially observed in patients from middle-income countries and those with concomitant APS. These results underscore the necessity for proactive and comprehensive CVD management in patients with APS, as well as SLE. Global-level individualized CVD risk stratification, recognition of MetS as a clinical entity in these patients, and thorough control of modifiable CVRFs similar to that implemented in other high CVD risk disorders are fundamental to providing high-quality care. Our results align with the recent EULAR recommendations prioritizing CVD management in SLE and APS patients, and support ongoing efforts to develop disease-specific CVD risk calculators and management strategies to effectively address the CVD burden in these populations.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Bolla, Eleana
  • Μπόλλα, Ελεάνα

Subjects

dc:subject × 16

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/58018

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Bolla, Eleana; Μπόλλα, Ελεάνα. Cardiovascular risk evaluation and attainment of therapeutic targets in antiphospholipid syndrome. National and Kapodistrian University of Athens, 2024. http://hdl.handle.net/10442/hedi/58018